{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:04:09Z","timestamp":1775657049318,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Cathay General Hospital and Fu-Jen University","award":["104-GGH-FJU-11"],"award-info":[{"award-number":["104-GGH-FJU-11"]}]},{"DOI":"10.13039\/501100004738","name":"E-Da Hospital","doi-asserted-by":"publisher","award":["EDAHP105019"],"award-info":[{"award-number":["EDAHP105019"]}],"id":[{"id":"10.13039\/501100004738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taipei Pathology Institutes","award":["TIP104-2"],"award-info":[{"award-number":["TIP104-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12876-017-0697-3","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T07:03:18Z","timestamp":1512716598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy"],"prefix":"10.1186","volume":"17","author":[{"given":"Nai-Hsuan","family":"Chien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Tsung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Shiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lein-Ray","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Ming","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzeng-Huey","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaw-Town","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"697_CR1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582\u201392.","journal-title":"Lancet"},{"key":"697_CR2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264\u201373.","journal-title":"Gastroenterology"},{"key":"697_CR3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The L","year":"2012","unstructured":"European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"697_CR4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661\u20132.","journal-title":"Hepatology"},{"key":"697_CR5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531\u201361.","journal-title":"Hepatol Int."},{"key":"697_CR6","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1517\/14656566.2011.590474","volume":"12","author":"CL Lin","year":"2011","unstructured":"Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother. 2011;12:2025\u201340.","journal-title":"Expert Opin Pharmacother"},{"key":"697_CR7","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang TT, Liaw YF, SS W, et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886\u201393.","journal-title":"Hepatology"},{"key":"697_CR8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468\u201375.","journal-title":"Lancet"},{"key":"697_CR9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","volume":"147","author":"W CY","year":"2014","unstructured":"CY W, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147:143\u201351.","journal-title":"Gastroenterology"},{"key":"697_CR10","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hep.27630","volume":"61","author":"CJ Chiang","year":"2015","unstructured":"Chiang CJ, Yang YW, Chen JD, et al. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology. 2015;61:1154\u201362.","journal-title":"Hepatology"},{"key":"697_CR11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","volume":"139","author":"JG Reijnders","year":"2010","unstructured":"Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010;139:491\u20138.","journal-title":"Gastroenterology"},{"key":"697_CR12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MCG.0b013e31825ceed9","volume":"46","author":"KT Chaung","year":"2012","unstructured":"Chaung KT, Ha NB, Trinh HN, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol. 2012;46:865\u201370.","journal-title":"J Clin Gastroenterol"},{"key":"697_CR13","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jis569","volume":"206","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, TH S, et al. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis. 2012;206:1521\u201331.","journal-title":"J Infect Dis"},{"key":"697_CR14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13150","volume":"41","author":"H Chi","year":"2015","unstructured":"Chi H, Hansen BE, Yim C, et al. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2015;41:867\u201376.","journal-title":"Aliment Pharmacol Ther"},{"key":"697_CR15","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/hep.24192","volume":"53","author":"J Fung","year":"2011","unstructured":"Fung J, Lai CL, Yuen J, et al. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2\u00a0Years. Hepatology. 2011;53:1148\u201353.","journal-title":"Hepatology"},{"key":"697_CR16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","volume":"61","author":"CH Chen","year":"2014","unstructured":"Chen CH, SN L, Hung CH, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol. 2014;61:515\u201322.","journal-title":"J Hepatol"},{"key":"697_CR17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3851\/IMP1921","volume":"16","author":"HL Chan","year":"2011","unstructured":"Chan HL, Wong GL, Chim AM, et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther. 2011;16:1249\u201357.","journal-title":"Antivir Ther"},{"key":"697_CR18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","volume":"64","author":"WK Seto","year":"2015","unstructured":"Seto WK, Hui AJ, Wong VW, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut. 2015;64:667\u201372.","journal-title":"Gut"},{"key":"697_CR19","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","volume":"58","author":"WJ Jeng","year":"2013","unstructured":"Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013;58:1888\u201396.","journal-title":"Hepatology"},{"key":"697_CR20","doi-asserted-by":"crossref","unstructured":"Hsu YC, Mo LR, Chang CY, et al. Association between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in E antigen-negative patients. Clin Gastroenterol Hepatol. 2016;14:1490-8.","DOI":"10.1016\/j.cgh.2016.03.024"},{"key":"697_CR21","doi-asserted-by":"crossref","unstructured":"Wang CC, Tseng KC, Hsieh TY, et al. Assessing the durability of Entecavir-treated hepatitis B using quantitative HBsAg. Am J Gastroenterol. 2016;111:1286-94.","DOI":"10.1038\/ajg.2016.109"},{"key":"697_CR22","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","volume":"63","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology. 2016;63:1481\u201392.","journal-title":"Hepatology."},{"key":"697_CR23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","volume":"52","author":"J Jaroszewicz","year":"2010","unstructured":"Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52:514\u201322.","journal-title":"J Hepatol."},{"key":"697_CR24","first-page":"992","volume":"52","author":"M Martinot-Peignoux","year":"2010","unstructured":"Martinot-Peignoux M, Lada O, Cardoso AC, et al. Quantitative HBsAg: a new specific marker for the diagnosis of HBsAg inactive carriage. Hepatology. 2010;52:992.","journal-title":"Hepatology."},{"key":"697_CR25","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/S0168-8278(11)60400-5","volume":"54","author":"M Yakut","year":"2011","unstructured":"Yakut M, Bektas M, Seven G, et al. Characterization of the inactive HBsAg carrier state with 3\u00a0year follow-up. J Hepatol. 2011;54:S159.","journal-title":"J Hepatol."},{"key":"697_CR26","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","volume":"13","author":"CH Chen","year":"2015","unstructured":"Chen CH, Hung CH, Hu TH, et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2015;13:1984\u201392.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"697_CR27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jhep.2010.10.027","volume":"55","author":"EK Manesis","year":"2011","unstructured":"Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol. 2011;55:61\u20138.","journal-title":"J Hepatol."},{"key":"697_CR28","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","volume":"5","author":"HL Chan","year":"2007","unstructured":"Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5:1462\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"697_CR29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","volume":"143","author":"C Boni","year":"2012","unstructured":"Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T Cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143:963\u201373.","journal-title":"Gastroenterology."},{"key":"697_CR30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","volume":"204","author":"R Zoutendijk","year":"2011","unstructured":"Zoutendijk R, Hansen BE, van Vuuren AJ, et al. Serum HBsAg decline during long-term potent nucleos(t) ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis. 2011;204:415\u20138.","journal-title":"J Infect Dis."},{"key":"697_CR31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3851\/IMP1866","volume":"16","author":"J Jaroszewicz","year":"2011","unstructured":"Jaroszewicz J, Ho H, Markova A, et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside\/nucleotide analogues. Antivir Ther. 2011;16:915\u201324.","journal-title":"Antivir Ther."},{"key":"697_CR32","doi-asserted-by":"crossref","unstructured":"Buti M, Casillas R, Riveiro-Barciela M, Homs M, Tabernero D, Salcedo MT, Rodriguez-Frias F, Esteban R. Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful? Clin Virol. 2015;68:61\u20138.","DOI":"10.1016\/j.jcv.2015.05.002"},{"key":"697_CR33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","volume":"118","author":"JH Kao","year":"2000","unstructured":"Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118:554\u20139.","journal-title":"Gastroenterology."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-017-0697-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T07:03:38Z","timestamp":1512716618000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-017-0697-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1186\/s12876-017-0697-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"154"}}